Mobile menu icon
Mobile menu icon Search iconSearch
Search type

Our vision and background

The Manchester Molecular Pathology Innovation Centre (MMPathIC) launched in October 2015 after The University of Manchester received £2.9 million to develop new tests based on molecular pathology techniques.


The Medical Research Council undertook a review of the UK molecular pathology landscape and released this in 2014.

The challenges identified by the MRC for getting new diagnostics and molecular pathology-based tests to the clinic were:

  • lack of a defined development pathway (for diagnostics);
  • a fragmented landscape (separation of the three key stakeholders: academia, pathology service and industry);
  • complexity (the challenge of integrating and interpreting numerous markers and multi-platform signatures).

To address these challenges, the MRC (with co-funding from the Engineering and Physical Sciences Council (EPSRC)) released a call for funding for a network of molecular pathology nodes.

The molecular pathology nodes were expected to each be a multidisciplinary centre of innovative molecular diagnostic test discovery and development bringing together the research base, pathology/genetic services and industry.

Six molecular pathology nodes were funded, including the Manchester node, MMPathIC. These nodes were expected to cooperate as a network in the evaluation and diffusion of next generation tests.


MMPathIC addresses these challenges through its pipeline model for working, which aims to bring key stakeholders (academia, clinical/ pathology service, and industry) into proximity, better define the developmental pathway, and offer cross-cutting training approaches to expand the skills base to support molecular pathology and diagnostic development.

The MMPathIC vision is to deliver at least six new biomarker tests or biomarker-based technologies to the clinic/market by October 2019.